BR0209254A - anticorpos de bloqueio cripto e usos dos mesmos - Google Patents

anticorpos de bloqueio cripto e usos dos mesmos

Info

Publication number
BR0209254A
BR0209254A BRPI0209254-9A BR0209254A BR0209254A BR 0209254 A BR0209254 A BR 0209254A BR 0209254 A BR0209254 A BR 0209254A BR 0209254 A BR0209254 A BR 0209254A
Authority
BR
Brazil
Prior art keywords
antibodies
crypto
bind
cripto
modulate
Prior art date
Application number
BRPI0209254-9A
Other languages
English (en)
Inventor
Michele Sanicola-Nadel
Kevin Williams
Susan Schiffer
Paul Rayhorn
Original Assignee
Biogen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27501437&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR0209254(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Biogen Inc filed Critical Biogen Inc
Publication of BR0209254A publication Critical patent/BR0209254A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

"ANTICORPOS DE BLOQUEIO CRIPTO E USOS DOS MESMOS". A invenção fornece anticorpos de bloqueio de Cripto, ou fragmentos biologicamente funcionais destes, e usos destes. Anticorpos que ligam Cripto e modulam a sinalização de Cripto são fornecidos. Anticorpos que ligam Cripto e bloqueiam a interação entre Cripto e ALK4 são fornecidos. Anticorpos que ligam Cripto e modulam o desenvolvimento de tumores também são fornecidos. Anticorpos que ligam Cripto, modulam a sinalização, e modulam o desenvolvimento de tumores também são fornecidos. Anticorpos que ligam Cripto, bloqueiam a interação entre Cripto e ALK4 e modulam o desenvolvimento de tumores são fornecidos. A invenção também fornece métodos para usar esses anticorpos em aplicações terapêuticas, diagnósticas, e de pesquisa.
BRPI0209254-9A 2001-04-26 2002-04-17 anticorpos de bloqueio cripto e usos dos mesmos BR0209254A (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US28678201P 2001-04-26 2001-04-26
US29302001P 2001-05-17 2001-05-17
US30109101P 2001-06-26 2001-06-26
US36700202P 2002-03-22 2002-03-22
PCT/US2002/011950 WO2002088170A2 (en) 2001-04-26 2002-04-17 Cripto blocking antibodies and uses thereof

Publications (1)

Publication Number Publication Date
BR0209254A true BR0209254A (pt) 2006-10-03

Family

ID=27501437

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0209254-9A BR0209254A (pt) 2001-04-26 2002-04-17 anticorpos de bloqueio cripto e usos dos mesmos

Country Status (34)

Country Link
US (6) US7531174B2 (pt)
EP (3) EP2316486A3 (pt)
JP (4) JP4307845B2 (pt)
KR (1) KR100592357B1 (pt)
CN (1) CN100352501C (pt)
AR (3) AR037223A1 (pt)
AT (2) ATE420659T1 (pt)
BG (1) BG108363A (pt)
BR (1) BR0209254A (pt)
CA (2) CA2715570A1 (pt)
CL (1) CL2009002199A1 (pt)
CY (1) CY1108960T1 (pt)
CZ (1) CZ20033208A3 (pt)
DE (1) DE60230868D1 (pt)
DK (1) DK1390389T3 (pt)
EA (1) EA007469B1 (pt)
EE (1) EE200300528A (pt)
ES (1) ES2321065T3 (pt)
GE (1) GEP20074091B (pt)
HK (1) HK1058935A1 (pt)
HU (1) HUP0501113A3 (pt)
IS (1) IS2662B (pt)
MX (1) MXPA03009797A (pt)
MY (2) MY157382A (pt)
NO (1) NO20034805L (pt)
NZ (1) NZ566268A (pt)
PL (1) PL207087B1 (pt)
PT (1) PT1390389E (pt)
RS (2) RS51635B (pt)
SG (1) SG157951A1 (pt)
SI (1) SI1390389T1 (pt)
SK (1) SK14432003A3 (pt)
TR (1) TR200301846T2 (pt)
WO (1) WO2002088170A2 (pt)

Families Citing this family (98)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002088170A2 (en) 2001-04-26 2002-11-07 Biogen, Inc. Cripto blocking antibodies and uses thereof
AUPR395801A0 (en) 2001-03-26 2001-04-26 Austin Research Institute, The Antibodies against cancer
US20090123470A1 (en) * 2001-03-26 2009-05-14 The Macfarlane Burnet Istitute For Medical Research And Public Health Ltd. Antibodies Against Cancer
US7582299B2 (en) 2001-04-26 2009-09-01 Biogen Idec Ma Inc. Cripto-specific antibodies
JP2005520566A (ja) * 2002-03-22 2005-07-14 バイオジェン・アイデック・エムエイ・インコーポレイテッド Ｃｒｉｐｔｏ特異的抗体
JP5091476B2 (ja) 2003-06-27 2012-12-05 バイオジェン・アイデック・エムエイ・インコーポレイテッド 均質な抗体溶液の生成のための疎水性相互作用クロマトグラフィーまたはヒンジ領域改変の使用
DE602004022315D1 (de) 2003-09-15 2009-09-10 Res Dev Foundation Cripto-antagonismus von activin und tgf-b signalisierung
CA3062320C (en) 2003-11-06 2022-11-15 Seattle Genetics, Inc. Monomethylvaline compounds capable of conjugation to ligands
EP2385069A3 (en) 2003-11-12 2012-05-30 Biogen Idec MA Inc. Neonatal Fc rReceptor (FcRn)- binding polypeptide variants, dimeric Fc binding proteins and methods related thereto
NZ579482A (en) 2004-06-01 2011-02-25 Genentech Inc Antibody drug conjugates and methods
PL1791565T3 (pl) 2004-09-23 2016-10-31 Modyfikowane cysteiną przeciwciała i koniugaty
US20100111856A1 (en) 2004-09-23 2010-05-06 Herman Gill Zirconium-radiolabeled, cysteine engineered antibody conjugates
WO2006074399A2 (en) 2005-01-05 2006-07-13 Biogen Idec Ma Inc. Multispecific binding molecules comprising connecting peptides
WO2006074397A2 (en) 2005-01-05 2006-07-13 Biogen Idec Ma Inc. Cripto binding molecules
AU2007279205B2 (en) 2006-07-28 2013-09-26 Children's Memorial Hospital Methods of inhibiting tumor cell aggressiveness using the microenvironment of human embryonic stem cells
US20100330081A1 (en) * 2007-06-01 2010-12-30 Biogen Idec Ma Inc. Cripto binding molecules
EP2279414A4 (en) * 2008-04-21 2011-06-29 Merck Sharp & Dohme PANCREATIC BETA CELL MASSE BIOMARKERS
EP2350131B1 (en) * 2008-11-07 2017-06-07 Research Development Foundation Compositions and methods for the inhibition of cripto/grp78 complex formation and signaling
JP2013504585A (ja) 2009-09-09 2013-02-07 セントローズ， エルエルシー 細胞外標的化薬物複合体
DK2528625T3 (da) 2010-04-15 2013-10-14 Spirogen Sarl Pyrrolobenzodiazepiner og konjugater deraf
BR112012030311A2 (pt) 2010-06-08 2017-01-24 Genentech Inc anticorpo
CN103313990B (zh) 2010-11-17 2016-07-20 基因泰克公司 丙氨酰美登醇抗体偶联物
CN110038135B (zh) 2011-03-17 2021-03-05 伯明翰大学 重新定向的免疫治疗
CN103826661B (zh) 2011-04-21 2019-03-05 西雅图基因公司 新的结合剂-药物缀合物(adc)及其用途
WO2012155019A1 (en) 2011-05-12 2012-11-15 Genentech, Inc. Multiple reaction monitoring lc-ms/ms method to detect therapeutic antibodies in animal samples using framework signature pepides
WO2013012733A1 (en) 2011-07-15 2013-01-24 Biogen Idec Ma Inc. Heterodimeric fc regions, binding molecules comprising same, and methods relating thereto
US11135303B2 (en) 2011-10-14 2021-10-05 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof
WO2013130093A1 (en) 2012-03-02 2013-09-06 Genentech, Inc. Biomarkers for treatment with anti-tubulin chemotherapeutic compounds
CA2887894C (en) 2012-10-12 2019-10-29 Adc Therapeutics Sarl Pyrrolobenzodiazepine - anti-psma antibody conjugates
CA2887895C (en) 2012-10-12 2019-10-29 Adc Therapeutics Sarl Pyrrolobenzodiazepine-anti-cd19 antibody conjugates
RS56520B1 (sr) 2012-10-12 2018-02-28 Adc Therapeutics Sa Pirolobenzodiazepin-anti-cd22 konjugati antitela
BR112015008232A2 (pt) 2012-10-12 2017-12-05 Adc Therapeutics Sarl conjugados pirrolbenzodiazepina-anticorpo
WO2014057120A1 (en) 2012-10-12 2014-04-17 Adc Therapeutics Sàrl Pyrrolobenzodiazepine-antibody conjugates
CA2885340C (en) 2012-10-12 2016-11-08 Spirogen Sarl Pyrrolobenzodiazepines and conjugates thereof
ES2680153T3 (es) 2012-10-12 2018-09-04 Adc Therapeutics Sa Conjugados de anticuerpos anti-PSMA-pirrolobenzodiazepinas
EP2935268B2 (en) 2012-12-21 2021-02-17 MedImmune Limited Pyrrolobenzodiazepines and conjugates thereof
CA2894959C (en) 2012-12-21 2022-01-11 Spirogen Sarl Unsymmetrical pyrrolobenzodiazepines-dimers for use in the treatment of proliferative and autoimmune diseases
EA027910B1 (ru) 2013-03-13 2017-09-29 Медимьюн Лимитед Пирролобензодиазепины и их конъюгаты
KR102066318B1 (ko) 2013-03-13 2020-01-14 메디뮨 리미티드 피롤로벤조디아제핀 및 그의 컨쥬게이트
JP6444902B2 (ja) 2013-03-13 2018-12-26 メドイミューン・リミテッドＭｅｄＩｍｍｕｎｅ Ｌｉｍｉｔｅｄ ピロロベンゾジアゼピン及びその結合体
KR20160042080A (ko) 2013-08-12 2016-04-18 제넨테크, 인크. 1-(클로로메틸)-2,3-디히드로-1H-벤조[e]인돌 이량체 항체-약물 접합체 화합물, 및 사용 및 치료 방법
EP3054983B1 (en) 2013-10-11 2019-03-20 Medimmune Limited Pyrrolobenzodiazepine-antibody conjugates
US9950078B2 (en) 2013-10-11 2018-04-24 Medimmune Limited Pyrrolobenzodiazepine-antibody conjugates
GB201317982D0 (en) 2013-10-11 2013-11-27 Spirogen Sarl Pyrrolobenzodiazepines and conjugates thereof
US9956299B2 (en) 2013-10-11 2018-05-01 Medimmune Limited Pyrrolobenzodiazepine—antibody conjugates
KR20170042495A (ko) 2013-12-16 2017-04-19 제넨테크, 인크. 펩티드모방체 화합물 및 그의 항체-약물 접합체
EP3082876B1 (en) 2013-12-16 2018-01-17 Genentech, Inc. 1-(chloromethyl)-2,3-dihydro-1h-benzo[e]indole dimer antibody-drug conjugate compounds, and methods of use and treatment
KR102354207B1 (ko) 2013-12-16 2022-01-20 제넨테크, 인크. 펩티드모방체 화합물 및 그의 항체-약물 접합체
NZ720736A (en) 2013-12-23 2020-08-28 Bayer Pharma AG Antibody drug conjugates (adcs) with kinesin spindel protein (ksp)
WO2016037644A1 (en) 2014-09-10 2016-03-17 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof
WO2016040825A1 (en) 2014-09-12 2016-03-17 Genentech, Inc. Anthracycline disulfide intermediates, antibody-drug conjugates and methods
BR112017003236A2 (pt) 2014-09-12 2017-11-28 Genentech Inc anticorpos elaborados com cisteína, conjugados de droga e anticorpos, método de preparação de conjugado de droga e anticorpo e composição farmacêutica
GB201416112D0 (en) 2014-09-12 2014-10-29 Medimmune Ltd Pyrrolobenzodiazepines and conjugates thereof
MX2017003523A (es) 2014-09-17 2017-11-08 Genentech Inc Pirrolobenzodiazepinas y conjugados de anticuerpo-disulfuro de las mismas.
CN107148285B (zh) 2014-11-25 2022-01-04 Adc治疗股份有限公司 吡咯并苯并二氮杂䓬-抗体缀合物
AU2015358532C1 (en) 2014-12-03 2020-10-29 Genentech, Inc. Quaternary amine compounds and antibody-drug conjugates thereof
CA2980611A1 (en) * 2015-04-07 2016-10-13 Paranta Biosciences Limited A method of treating neoplasias
GB201506402D0 (en) 2015-04-15 2015-05-27 Berkel Patricius H C Van And Howard Philip W Site-specific antibody-drug conjugates
GB201506411D0 (en) 2015-04-15 2015-05-27 Bergenbio As Humanized anti-axl antibodies
CA2990076A1 (en) 2015-06-22 2016-12-29 Bayer Pharma Aktiengesellschaft Antibody drug conjugates (adcs) and antibody prodrug conjugates (apdcs) with enzymatically cleavable groups
MA43345A (fr) 2015-10-02 2018-08-08 Hoffmann La Roche Conjugués anticorps-médicaments de pyrrolobenzodiazépine et méthodes d'utilisation
WO2017060322A2 (en) 2015-10-10 2017-04-13 Bayer Pharma Aktiengesellschaft Ptefb-inhibitor-adc
MA43354A (fr) 2015-10-16 2018-08-22 Genentech Inc Conjugués médicamenteux à pont disulfure encombré
MA45326A (fr) 2015-10-20 2018-08-29 Genentech Inc Conjugués calichéamicine-anticorps-médicament et procédés d'utilisation
GB201601431D0 (en) 2016-01-26 2016-03-09 Medimmune Ltd Pyrrolobenzodiazepines
GB201602359D0 (en) 2016-02-10 2016-03-23 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
GB201602356D0 (en) 2016-02-10 2016-03-23 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
MX2018011627A (es) 2016-03-24 2019-01-10 Bayer Pharma AG Profarmacos de farmacos citotoxicos que tienen grupos enzimaticamente escindibles.
JP6943872B2 (ja) 2016-03-25 2021-10-06 ジェネンテック， インコーポレイテッド 多重全抗体及び抗体複合体化薬物定量化アッセイ
GB201607478D0 (en) 2016-04-29 2016-06-15 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
ES2858151T3 (es) 2016-05-20 2021-09-29 Hoffmann La Roche Conjugados de PROTAC-anticuerpo y procedimientos de uso
WO2017205741A1 (en) 2016-05-27 2017-11-30 Genentech, Inc. Bioanalytical method for the characterization of site-specific antibody-drug conjugates
US10639378B2 (en) 2016-06-06 2020-05-05 Genentech, Inc. Silvestrol antibody-drug conjugates and methods of use
EP3471776B1 (en) 2016-06-15 2022-05-04 Bayer Pharma Aktiengesellschaft Specific antibody-drug-conjugates with ksp inhibitors and anti-cd123-antibodies
EP3496763A1 (en) 2016-08-11 2019-06-19 Genentech, Inc. Pyrrolobenzodiazepine prodrugs and antibody conjugates thereof
WO2018065501A1 (en) 2016-10-05 2018-04-12 F. Hoffmann-La Roche Ag Methods for preparing antibody drug conjugates
GB201617466D0 (en) 2016-10-14 2016-11-30 Medimmune Ltd Pyrrolobenzodiazepine conjugates
CA3047491A1 (en) 2016-12-21 2018-06-28 Bayer Aktiengesellschaft Prodrugs of cytotoxic active agents having enzymatically cleavable groups
AU2017380871A1 (en) 2016-12-21 2019-07-11 Bayer Aktiengesellschaft Antibody drug conjugates (ADCs) having enzymatically cleavable groups
JP7030811B2 (ja) 2016-12-21 2022-03-07 バイエル・ファルマ・アクティエンゲゼルシャフト Ｋｓｐ阻害剤を有する特異的抗体－薬物コンジュゲート（ａｄｃ）
GB201702031D0 (en) 2017-02-08 2017-03-22 Medlmmune Ltd Pyrrolobenzodiazepine-antibody conjugates
CN110267686B (zh) 2017-02-08 2023-06-09 Adc治疗有限公司 吡咯并苯并二氮杂䓬-抗体缀合物
WO2018192944A1 (en) 2017-04-18 2018-10-25 Medimmune Limited Pyrrolobenzodiazepine conjugates
CA3057748A1 (en) 2017-04-20 2018-10-25 Adc Therapeutics Sa Combination therapy with an anti-axl antibody-drug conjugate
CA3064804A1 (en) 2017-06-14 2018-12-20 Adc Therapeutics Sa Dosage regimes for the administration of an anti-cd19 adc
SG11202000358YA (en) 2017-08-18 2020-02-27 Medimmune Ltd Pyrrolobenzodiazepine conjugates
BR112020004307A2 (pt) 2017-09-20 2020-11-10 Ph Pharma Co., Ltd. análogos de tailanestatina
GB201803342D0 (en) 2018-03-01 2018-04-18 Medimmune Ltd Methods
GB201806022D0 (en) 2018-04-12 2018-05-30 Medimmune Ltd Pyrrolobenzodiazepines and conjugates thereof
BR112020024549A2 (pt) 2018-06-01 2021-03-02 Eisai R&D Management Co., Ltd. conjugados anticorpo-fármaco de modulador de splicing e métodos de uso
GB201814281D0 (en) 2018-09-03 2018-10-17 Femtogenix Ltd Cytotoxic agents
TW202037381A (zh) 2018-10-24 2020-10-16 瑞士商赫孚孟拉羅股份公司 綴合化學降解誘導劑及使用方法
WO2020123275A1 (en) 2018-12-10 2020-06-18 Genentech, Inc. Photocrosslinking peptides for site specific conjugation to fc-containing proteins
CN113271981A (zh) 2018-12-13 2021-08-17 卫材R&D管理有限公司 荷伯希二烯抗体-药物缀合物及使用方法
US11702482B2 (en) 2018-12-17 2023-07-18 Revitope Limited Twin immune cell engager
GB201901197D0 (en) 2019-01-29 2019-03-20 Femtogenix Ltd G-A Crosslinking cytotoxic agents
GB2597532A (en) 2020-07-28 2022-02-02 Femtogenix Ltd Cytotoxic compounds
WO2024138128A2 (en) 2022-12-23 2024-06-27 Genentech, Inc. Cereblon degrader conjugates, and uses thereof

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ207394A (en) * 1983-03-08 1987-03-06 Commw Serum Lab Commission Detecting or determining sequence of amino acids
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JP3040121B2 (ja) 1988-01-12 2000-05-08 ジェネンテク，インコーポレイテッド 増殖因子レセプターの機能を阻害することにより腫瘍細胞を処置する方法
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5208020A (en) * 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
US5780029A (en) 1989-11-14 1998-07-14 New York Medical College Antidiotypic monoclonal antibodies for treatment of melanoma
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
US5256643A (en) 1990-05-29 1993-10-26 The Government Of The United States Human cripto protein
EP0814159B1 (en) 1990-08-29 2005-07-27 GenPharm International, Inc. Transgenic mice capable of producing heterologous antibodies
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
US5264557A (en) 1991-08-23 1993-11-23 The United States Of America As Represented By The Department Of Health And Human Services Polypeptide of a human cripto-related gene, CR-3
US6063379A (en) 1993-12-09 2000-05-16 Centro De Inmunologia Molecular Anti-idiotypic monoclonal antibodies and compositions including the anti-idiotypic monoclonal antibodies
US5981215A (en) * 1995-06-06 1999-11-09 Human Genome Sciences, Inc. Human criptin growth factor
IL127193A (en) * 1996-05-22 2006-10-31 Viventia Biotech Inc Antigen binding fragments that specifically detect cancer cells, nucleotides encoding the fragments and use thereof for the prophylaxis and detection of cancers
IL125608A0 (en) 1998-07-30 1999-03-12 Yeda Res & Dev Tumor associated antigen peptides and use of same as anti-tumor vaccines
TR200200735T2 (tr) 1998-12-23 2002-06-21 Pfizer Inc. CTLA-4 için insan monoklonal antikorları
WO2000052204A2 (en) * 1999-02-22 2000-09-08 Orntoft Torben F Gene expression in bladder tumors
CA2368734C (en) 1999-03-30 2005-08-23 Japan Tobacco Inc. Method for preparing monoclonal antibody
EP1179178A1 (en) * 1999-04-20 2002-02-13 William J. Kokolus Improved method of identifying and locating immunobiologically-active linear peptides
US6833268B1 (en) 1999-06-10 2004-12-21 Abgenix, Inc. Transgenic animals for producing specific isotypes of human antibodies via non-cognate switch regions
JP2001046066A (ja) 1999-08-03 2001-02-20 Kyowa Hakko Kogyo Co Ltd 新規な相補性決定領域を有するヒトｖｅｇｆ受容体ｋｄｒに対する抗体
CN1413220A (zh) 1999-10-29 2003-04-23 杰南技术公司 抗***干细胞抗原(psca)抗体组合物及其应用方法
US6663613B1 (en) 2000-01-25 2003-12-16 Bacchus Vascular, Inc. System and methods for clot dissolution
KR100890873B1 (ko) * 2000-03-03 2009-03-31 교와 핫꼬 기린 가부시키가이샤 유전자 재조합 항체 및 이의 항체 단편
WO2002088170A2 (en) * 2001-04-26 2002-11-07 Biogen, Inc. Cripto blocking antibodies and uses thereof
US6333410B1 (en) * 2000-08-18 2001-12-25 Immunogen, Inc. Process for the preparation and purification of thiol-containing maytansinoids
GB0020953D0 (en) 2000-08-24 2000-10-11 Smithkline Beecham Biolog Vaccine
WO2002022808A2 (en) 2000-09-18 2002-03-21 Biogen, Inc. Cripto mutant and uses thereof
EP1370869B1 (en) 2001-01-26 2006-12-27 The Government of the United States of America as represented by the Secretary of the Department of Health and Human Services Detection and quantification of cripto-1
WO2002096948A2 (en) 2001-01-29 2002-12-05 Idec Pharmaceuticals Corporation Engineered tetravalent antibodies and methods of use
WO2002060955A2 (en) 2001-01-29 2002-08-08 Idec Pharmaceuticals Corporation Modified antibodies and methods of use
AUPR395801A0 (en) 2001-03-26 2001-04-26 Austin Research Institute, The Antibodies against cancer
US7582299B2 (en) * 2001-04-26 2009-09-01 Biogen Idec Ma Inc. Cripto-specific antibodies
KR101008758B1 (ko) * 2001-09-18 2011-01-14 제넨테크, 인크. 종양의 진단 및 치료를 위한 방법 및 이를 위한 조성물
US20040014690A1 (en) * 2002-02-13 2004-01-22 Zhenkun Ma Macrolides with activity against methicillin-resistant staphylococcus aureus
JP2005520566A (ja) * 2002-03-22 2005-07-14 バイオジェン・アイデック・エムエイ・インコーポレイテッド Ｃｒｉｐｔｏ特異的抗体
DE602004022315D1 (de) * 2003-09-15 2009-09-10 Res Dev Foundation Cripto-antagonismus von activin und tgf-b signalisierung
WO2006074397A2 (en) * 2005-01-05 2006-07-13 Biogen Idec Ma Inc. Cripto binding molecules
EP2021510A2 (en) * 2006-04-28 2009-02-11 Biogen Idec MA Inc. Composition and methods for the detection of cripto-3

Also Published As

Publication number Publication date
US20090285818A1 (en) 2009-11-19
EP2316486A3 (en) 2011-09-07
BG108363A (bg) 2004-09-30
EP1390389A2 (en) 2004-02-25
PT1390389E (pt) 2009-04-03
US20100202962A1 (en) 2010-08-12
US20120195912A1 (en) 2012-08-02
US7888052B2 (en) 2011-02-15
IS6999A (is) 2003-10-24
JP4575983B2 (ja) 2010-11-04
IS2662B (is) 2010-08-15
DE60230868D1 (de) 2009-03-05
US20040146940A1 (en) 2004-07-29
CA2443840A1 (en) 2002-11-07
JP2009108100A (ja) 2009-05-21
NZ566268A (en) 2009-09-25
MY157382A (en) 2016-06-15
US20080166341A1 (en) 2008-07-10
JP2004534020A (ja) 2004-11-11
HK1058935A1 (en) 2004-06-11
EP1974749A1 (en) 2008-10-01
CN100352501C (zh) 2007-12-05
WO2002088170A2 (en) 2002-11-07
EE200300528A (et) 2004-08-16
ES2321065T3 (es) 2009-06-02
YU84903A (sh) 2006-05-25
HUP0501113A3 (en) 2007-12-28
PL207087B1 (pl) 2010-10-29
JP4307845B2 (ja) 2009-08-05
SG157951A1 (en) 2010-01-29
EP1390389B1 (en) 2009-01-14
MXPA03009797A (es) 2004-01-29
US20090286265A1 (en) 2009-11-19
JP2010163438A (ja) 2010-07-29
CZ20033208A3 (en) 2004-03-17
NO20034805L (no) 2003-12-23
US7531174B2 (en) 2009-05-12
CL2009002199A1 (es) 2010-05-07
RS51635B (sr) 2011-08-31
WO2002088170A3 (en) 2003-12-24
US8673303B2 (en) 2014-03-18
NO20034805D0 (no) 2003-10-27
HUP0501113A2 (en) 2007-05-02
ATE533508T1 (de) 2011-12-15
SK14432003A3 (sk) 2004-07-07
EA200301158A1 (ru) 2005-06-30
US7674462B2 (en) 2010-03-09
MY150237A (en) 2013-12-31
ATE420659T1 (de) 2009-01-15
PL373513A1 (en) 2005-09-05
CN1606453A (zh) 2005-04-13
GEP20074091B (en) 2007-04-25
KR100592357B1 (ko) 2006-06-22
AR037223A1 (es) 2004-11-03
CA2715570A1 (en) 2002-11-07
EP2316486A2 (en) 2011-05-04
EP1390389A4 (en) 2004-09-22
CY1108960T1 (el) 2014-07-02
CA2443840C (en) 2010-10-26
AR077759A2 (es) 2011-09-21
SI1390389T1 (sl) 2009-06-30
TR200301846T2 (tr) 2006-10-26
EA007469B1 (ru) 2006-10-27
KR20040028744A (ko) 2004-04-03
JP2005314436A (ja) 2005-11-10
EP1974749B1 (en) 2011-11-16
DK1390389T3 (da) 2009-04-20
US8003763B2 (en) 2011-08-23
AR072554A2 (es) 2010-09-08
RS20110024A (en) 2011-08-31

Similar Documents

Publication Publication Date Title
BR0209254A (pt) anticorpos de bloqueio cripto e usos dos mesmos
CY1119291T1 (el) Πολυσθενη αντισωματα και χρησεις για αυτα
ATE444967T1 (de) Spezifische bindungsmittel von human angiopoietin-2
MY136095A (en) Use of human anti-ctla-4 antibodies for treatment of cancer
DE60032486D1 (de) Prion protein peptide und deren verwendung
MXPA02011656A (es) Moleculas de acido nucleico nrg-2, polipeptidos, y metodos de diagnostico y terapeuticos.
DE60331049D1 (de) Konjugate von zytotoxischen mitteln und biologisch aktiven peptiden
IS6560A (is) Lyfjasamsetning fyrir meðhöndlun á bráðum, þrálátum sársauka og/eða taugakerfissársauka og mígreni
DE69838979D1 (de) Rekombinante antikörper und immunkonjugate gezielt auf cd22-tragende zellen und tumoren
DE60239707D1 (de) Antimikrobielle kationische peptide und diese enthaltende formulierungen
BR0306715A (pt) Métodos para diagnóstico e tratamento de tumores
DE69435307D1 (de) Bazillus Thuringiensis und dessen insektizide Proteine
DK1572087T3 (da) Antistoffer med cancerantigen TMEFF2 og anvendelser deraf
WO2003104425A3 (en) NEW STABLE ANTI-CD22 ANTIBODIES
DE69133068D1 (de) Tumor-zerstörende effekte von enterotoxinen und verwandten verbindungen
DE69714451D1 (de) Prionbindende proteine und deren verwendungen
BR0109164A (pt) Anticorpos monoclonais para o receptor humano para ldl, produção e uso dos mesmos
DE60224667D1 (de) Perylenequinonen zur anwendung als sonosensitizer
NO20005548D0 (no) Mykobakterieinhibitorer
ATE328082T1 (de) Verkürztes bard1 protein und dessen diagnostische und therapeutische anwendungen
ATE490981T1 (de) Criptospezifische antikörper
DK1133297T3 (da) Ny terapeutisk anvendelse af 1,6-dimethyl-8beta-hydroxymethyl-10alpha-methoxyergolin

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 11A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2232 DE 15/10/2013.